Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter

Ginkgo Bioworks (NYSE:DNA) shares are down following the company’s fourth-quarter and full-year 2025 financial report.The stock’s decline comes as the company is focusing on investing in autonomous labs.Divests Non-Core Business To Focus On RoboticsFor the fourth quarter of 2025, Ginkgo Bioworks reported a strategic pivot towards robotics and AI, with CEO Jason Kelly emphasizing the company’s collaboration with the Department of Energy and OpenAI.The company also announced plans to divest its biosecurity bu ...